Grifols GIFLF
NASDAQ GIFLF
$11.08 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Grifols (GIFLF) Share-based Compensation (2012 - 2022)

Grifols' (GIFLF) quarterly Share-based Compensation came in at -$3.5 million in Q4 2022, down 102.59% quarter-over-quarter from $136.3 million in Q4 2013.

Analysis

Grifols (GIFLF) Share-based Compensation (2012 - 2022) Analysis & Trends

Grifols (GIFLF) has reported Share-based Compensation for 3 consecutive years, with -$3.5 million the latest figure, recorded in Q4 2022.

  • For the quarter ending Q4 2022, Share-based Compensation changed N/A year-over-year to -$3.5 million; the trailing twelve-month figure through Dec 2022 stood at -$3.5 million (changed N/A YoY), and the FY2022 full-year result was -$3.5 million, up 97.55% from the prior year.
  • Share-based Compensation declined to -$3.5 million in Q4 2022 per GIFLF's latest filing, from $136.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at -$3.5 million in Q4 2022 and bottomed at -$3.5 million in Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn 247.00 Mn
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn 231.00 Mn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn 108.10 Mn
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn 243.00 Mn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn -
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn 120.00 Mn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn 86.63 Mn
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn 77.40 Mn
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn 83.34 Mn
10 Grifols 7.54 Bn 9.09 Bn 3.33 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 -3.53 Mn
Dec 31, 2013 136.26 Mn
Dec 31, 2012 6.72 Mn